[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,653,924
  • Shares Outstanding, K 115,821
  • Annual Sales, $ 655,350 K
  • Annual Income, $ -136,230 K
  • EBIT $ -183 M
  • EBITDA $ -192 M
  • 60-Month Beta 0.93
  • Price/Sales 3.15
  • Price/Cash Flow N/A
  • Price/Book 6.25

Options Overview Details

View History
  • Implied Volatility 64.08% (-7.72%)
  • Historical Volatility 85.20%
  • IV Percentile 30%
  • IV Rank 15.86%
  • IV High 152.45% on 03/18/26
  • IV Low 47.41% on 05/21/26
  • Expected Move (DTE 27) 0.63 (4.40%)
  • Put/Call Vol Ratio 1.16
  • Today's Volume 1,646
  • Volume Avg (30-Day) 545
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 30,566
  • Open Int (30-Day) 27,202
  • Expected Range 13.65 to 14.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.34
  • Number of Estimates 4
  • High Estimate $-0.23
  • Low Estimate $-0.47
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) +5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.88 +2.88%
on 06/18/26
18.67 -23.51%
on 05/26/26
-3.18 (-18.21%)
since 05/18/26
3-Month
10.14 +40.90%
on 04/07/26
18.92 -24.52%
on 05/11/26
+2.22 (+18.41%)
since 03/18/26
52-Week
9.82 +45.42%
on 02/09/26
18.92 -24.52%
on 05/11/26
-2.52 (-15.00%)
since 06/18/25

Most Recent Stories

More News
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)

Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday...

NVCR : 14.28 (-20.00%)
Stocks Sharply Higher as US-Iran Peace Deal Eases Inflation Risks

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +1.08%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.48%. September E-mini...

ALK : 49.26 (+2.05%)
SNDK : 2,184.75 (+11.54%)
ADI : 434.46 (+4.83%)
SLB : 48.09 (-4.45%)
OXY : 51.82 (-2.30%)
NVCR : 14.28 (-20.00%)
FANG : 183.50 (-1.07%)
AMD : 537.37 (+4.86%)
VRT : 333.05 (+4.87%)
CTSH : 43.70 (-10.49%)
SPY : 746.74 (+1.04%)
MU : 1,133.99 (+8.70%)
Stocks Supported as Geopolitical Risks Recede

The S&P 500 Index ($SPX ) (SPY ) today is up +0.99%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.61%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.16%. September E-mini S&P futures...

ALK : 49.26 (+2.05%)
SNDK : 2,184.75 (+11.54%)
ADI : 434.46 (+4.83%)
SLB : 48.09 (-4.45%)
OXY : 51.82 (-2.30%)
NVCR : 14.28 (-20.00%)
FANG : 183.50 (-1.07%)
CTSH : 43.70 (-10.49%)
SPY : 746.74 (+1.04%)
MU : 1,133.99 (+8.70%)
BKR : 58.41 (-2.76%)
HURN : 90.56 (-14.73%)
Stocks Rally as President Trump Signs a Preliminary Deal to End the US-Iran War

The S&P 500 Index ($SPX ) (SPY ) today is up +0.73%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.53%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.62%. June E-mini S&P futures (ESM26...

ALK : 49.26 (+2.05%)
AMAT : 617.11 (+4.08%)
UAL : 118.32 (+2.15%)
SNDK : 2,184.75 (+11.54%)
ADI : 434.46 (+4.83%)
TXN : 322.86 (+6.95%)
$IUXX : 30,406.19 (unch)
ZNU26 : 109-105 (-0.27%)
NVCR : 14.28 (-20.00%)
ESU26 : 7,556.25s (-0.19%)
FDS : 221.29 (-3.07%)
NCLH : 20.44 (+3.08%)
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

The Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start of...

NVCR : 14.28 (-20.00%)
NovoCure: Q1 Earnings Snapshot

NovoCure: Q1 Earnings Snapshot

NVCR : 14.28 (-20.00%)
Novocure Reports First Quarter 2026 Financial Results

Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced...

NVCR : 14.28 (-20.00%)
NovoCure's Narrowing Losses Could Signal a Turning Point for Optune Adoption

Barchart Research What to Expect from NVCR Earnings NVCR Generated April 29, 2026 Current Price $11.93 EPS Estimate $$-0.40 Consensus Rating Moderate Buy Average Move 8.34% NovoCure's Narrowing Losses...

NVCR : 14.28 (-20.00%)
Novocure to Report First Quarter 2026 Financial Results

Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and...

NVCR : 14.28 (-20.00%)
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq ® ), ...

NVCR : 14.28 (-20.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 16.18
2nd Resistance Point 15.64
1st Resistance Point 14.96
Last Price 14.28
1st Support Level 13.74
2nd Support Level 13.20
3rd Support Level 12.52

See More

52-Week High 18.92
Fibonacci 61.8% 15.44
Fibonacci 50% 14.37
Last Price 14.28
Fibonacci 38.2% 13.30
52-Week Low 9.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.